Minoryx Raises EUR 51M in Sequence C Funding

Minoryx Therapeutics

Minoryx Therapeutics, a Mataró, Barcelona, Spain-based Part 3 stage biotech firm centered on the event of therapies for orphan central nervous system (CNS) problems, closed a EUR 51m financing, together with Sequence C fairness financing and complementary financial institution debt.

The spherical was co-led by Columbus Enterprise Companions and Caixa Capital Risc. Dr. Damià Tormo, representing Columbus Enterprise Companions, has joined Minoryx’s Board of Administrators. CDTI, via its Innvierte program, additionally joined the Sequence C spherical which was additionally supported by current Sequence B buyers, led by Fund+ and its Belgian Public co-investors, and Sequence A buyers, led by Ysios Capital.

The corporate will use the funding to finance the advertising and marketing authorization utility (MAA) and launch preparations of its drug candidate leriglitazone for grownup male X-ALD sufferers with adrenomyeloneuropathy (AMN) within the EU, in direction of the approval of leriglitazone within the US for a similar indication. Lastly, the proceeds will assist the continuation of leriglitazone’s improvement in pediatric sufferers with cerebral ALD (cALD) in addition to label enlargement into girls affected by X-ALD.

Leriglitazone, a novel mind penetrant PPAR gamma agonist, has proven important medical profit in Minoryx’s ADVANCE Part II/III medical trial in grownup male sufferers with AMN. On this examine, leriglitazone diminished the development of cerebral lesions and myelopathy signs. These information additionally assist Minoryx’s ongoing NEXUS examine, an open-label part II/III trial assessing leriglitazone in male pediatric sufferers with early stage cALD.

Led by Marc Martinell, CEO, Minoryx is a medical stage biotech firm specializing in the event of novel therapies for orphan CNS illnesses with excessive unmet medical wants. The corporate’s lead program, leriglitazone (MIN-102), a novel, mind penetrant and selective PPARγ agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and different CNS illnesses akin to Friedreich’s ataxia.

Minoryx additionally has Belgian services.

Get latest news from African Startup ecosystem

Latest stories

You might also like...